D K Murray - JoVE Visualize

Showing results (21-30 of 26) with videos related to

Pageof 3

Sort By:

You have reached the last page of results.This site can display upto 26 results.

Metabolism: Clinical and Experimental|September 14, 1999

Transforming growth factor beta-1 and beta-2 and type II receptor functional regulation of ALVA-101 human prostate cancer cellsA W Meikle, R E Swope, D Y Yin, et al.

The Journal of Clinical Endocrinology and Metabolism|March 17, 2000

Heritability of prostate-specific antigen and relationship with zonal prostate volumes in aging twinsA Bansal, D K Murray, J T Wu, et al.

Journal of Molecular Endocrinology|September 21, 2001

A spontaneously arising mutation in connexin32 with repeated passage of FRTL-5 cells coincides with increased growth rate and reduced thyroxine releaseL M Green, D K Murray, D T Tran, et al.

Radiation Research|December 20, 2000

Response of thyroid follicular cells to gamma irradiation compared to proton irradiation. I. Initial characterization of DNA damage, micronucleus formation, apoptosis, cell survival, and cell cycle phase redistributionL M Green, D K Murray, A M Bant, et al.

Journal of Medicinal Chemistry|December 16, 1997

Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptorA M Thompson, D K Murray, W L Elliott, et al.

Journal of Medicinal Chemistry|March 26, 1998

Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factorsG W Rewcastle, D K Murray, W L Elliott, et al.

Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:

Pageof 3

You have reached the last page of results.This site can display upto 26 results.

Metabolism: Clinical and Experimental|September 14, 1999

Transforming growth factor beta-1 and beta-2 and type II receptor functional regulation of ALVA-101 human prostate cancer cellsA W Meikle, R E Swope, D Y Yin, et al.

The Journal of Clinical Endocrinology and Metabolism|March 17, 2000

Heritability of prostate-specific antigen and relationship with zonal prostate volumes in aging twinsA Bansal, D K Murray, J T Wu, et al.

Journal of Molecular Endocrinology|September 21, 2001

A spontaneously arising mutation in connexin32 with repeated passage of FRTL-5 cells coincides with increased growth rate and reduced thyroxine releaseL M Green, D K Murray, D T Tran, et al.

Radiation Research|December 20, 2000

Response of thyroid follicular cells to gamma irradiation compared to proton irradiation. I. Initial characterization of DNA damage, micronucleus formation, apoptosis, cell survival, and cell cycle phase redistributionL M Green, D K Murray, A M Bant, et al.

Journal of Medicinal Chemistry|December 16, 1997

Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptorA M Thompson, D K Murray, W L Elliott, et al.

Journal of Medicinal Chemistry|March 26, 1998

Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factorsG W Rewcastle, D K Murray, W L Elliott, et al.

Pageof 3